Background Beta-lactam antibiotics (βLA) are the most commonly used antibiotics in the
intensive care unit (ICU). ICU patients present many pathophysiological features that cause …

Physiologic alterations seen in obesity commonly impact the pharmacokinetics (PK) and
pharmacodynamics (PD) of antibiotics and may result in suboptimal dosing in this …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …

What is known and objective Meropenem, a carbapenem antibiotic, is widely prescribed for
the treatment of life‐threatening infections. The main parameter associated with its …

The increased prevalence of obesity presents challenges for clinicians aiming to provide
optimised antimicrobial dosing in the intensive care unit. Obesity is likely to exacerbate the …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

This objective of this study was to compare clinical outcomes in hospitalized patients with
Pseudomonas aeruginosa pneumonia (PNA) or bloodstream infection (BSI) receiving beta …

To perform a systematic review with meta-analysis with the dual intent of assessing the
impact of attaining aggressive vs. conservative beta-lactams PK/PD target on the clinical …

Introduction: Emerging studies suggest that antibiotic pharmacokinetics (PK) are difficult to
predict in critically ill patients. The high intra-and inter-patient PK variability makes it …

Severe pathophysiological changes in critical illness can lead to dramatically altered
antimicrobial pharmacokinetics (PK). The additional effect of obesity on PK potentially …